Analyzing Optimer Pharmaceuticals (OPTR) & Anika Therapeutics (ANIK)
Optimer Pharmaceuticals (NASDAQ: OPTR) and Anika Therapeutics (NASDAQ:ANIK) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Institutional and Insider Ownership
84.9% of Anika Therapeutics shares are owned by institutional investors. 6.6% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Optimer Pharmaceuticals and Anika Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anika Therapeutics||$103.38 million||7.87||$32.54 million||$2.12||26.19|
Anika Therapeutics has higher revenue and earnings than Optimer Pharmaceuticals. Optimer Pharmaceuticals is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Optimer Pharmaceuticals and Anika Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Optimer Pharmaceuticals and Anika Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Anika Therapeutics has a consensus price target of $57.00, suggesting a potential upside of 2.65%.
Anika Therapeutics beats Optimer Pharmaceuticals on 8 of the 8 factors compared between the two stocks.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company’s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer’s products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.
About Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Receive News & Ratings for Optimer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Optimer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.